MASAC Issues Two New Documents
In December 2018, the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation issued two new documents:
Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia A with and without Inhibitors
MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia
Both documents can be found on the NHF website at https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations. We encourage you to review these documents and discuss them with your hematologist.